The KBI Biopharma agreement provides that KBI Biopharma will manufacture and deliver production quantities of CHS-1701 for the planned commercial launch of CHS-1701 and multiple years of commercial...
Complix will have access to the Selexis SUREtechnology Platform™ for the production of high-expressing and stable clonal cell lines for use in the development and commercial manufacturing of CMX-02.
Receive JSR Life Sciences news on your RSS reader.